scholarly journals Corrigendum to ’The survival time of restorations is shortened in patients with dry mouth’ [Journal of Dentistry 113 (2021) 103794]

2022 ◽  
pp. 103945
Author(s):  
Jukka Leinonen ◽  
Hannu Vähänikkilä ◽  
Ellinoora Raninen ◽  
Laura Järvelin ◽  
Ritva Näpänkangas ◽  
...  
Keyword(s):  
2021 ◽  
pp. 103794
Author(s):  
Leinonen Jukka ◽  
Vähänikkilä Hannu ◽  
Raninen Ellinoora ◽  
Järvelin Laura ◽  
Näpänkangas Ritva ◽  
...  
Keyword(s):  

2020 ◽  
Vol 7 (2) ◽  
pp. 107-112
Author(s):  
Marian Manciu ◽  
Sorour Hosseini ◽  
Joscelyne Guzman-Gonzalez

Background: Statistical methods commonly used in survival analysis typically provide the probability that the difference between groups is due to chance, but do not offer a reliable estimate of the average survival time difference between groups (the difference between median survival time is usually reported). Objective: We suggest a Maximum-Entropy estimator for the average Survival Time Difference (MESTD) between groups. Methods: The estimator is based on the extra survival time, which should be added to each member of the group, to produce the maximum entropy of the result (resulting in the groups becoming most similar). The estimator is calculated only from time to event data, does not necessarily assume hazard proportionality and provides the magnitude of the clinical differences between the groups. Results: Monte Carlo simulations show that, even at low sample numbers (much lower than the ones needed to prove that the two groups are statistically different), the MESTD estimator is a reliable predictor of the clinical differences between the groups, and therefore can be used to estimate from (low sample numbers) preliminary data whether or not the large sample number experiment is worth pursuing. Conclusion: By providing a reasonable estimate for the efficacy of a treatment (e.g., for cancer) even for low sample data, it might provide useful insight in testing new methods for treatment (for example, for quick testing of multiple combinations of cancer drugs).


2020 ◽  
Vol 154 (2) ◽  
pp. 208-214
Author(s):  
Michael J Hwang ◽  
Ashish M Kamat ◽  
Colin P Dinney ◽  
Bogdan Czerniak ◽  
Charles C Guo

Abstract Objectives Bladder cancers invading the muscularis mucosae (MM) are treated differently from those invading the muscularis propria (MP). However, it may be difficult to determine the type of smooth muscle in transurethral resection (TUR) or biopsy specimens. We aimed to investigate the clinicopathologic features of bladder cancers involving smooth muscle of indeterminate type (SMIT) in TUR specimens in comparison with those invading the MM. Methods We identified 103 patients with bladder cancer involving SMIT (n = 27) or the MM (n = 76) in TUR specimens. All patients underwent subsequent restaging TUR or cystectomy. Results Bladder cancer with SMIT invasion showed a significantly higher rate of MP invasion in the subsequent specimens than those invading the MM (52% vs 29%). Lack of MP in the TUR specimens had a significantly higher risk of MP invasion in the subsequent specimens than those with the MP (61% vs 40%). The overall survival time for patients with SMIT invasion was significantly shorter than those with MM invasion. Conclusions Bladder cancers with SMIT invasion in TUR specimens show more frequent cancer upstaging in the subsequent specimens and a poorer clinical outcome than those invading the MM, which highlights the importance of a cancer restaging procedure for these patients.


Sign in / Sign up

Export Citation Format

Share Document